CNS Pharmaceuticals, Inc.

GRI Bio, Inc.

Cartesian Therapeutics, Inc.

Viridian Therapeutics, Inc.

Jazz Pharmaceuticals plc

Compass Therapeutics, Inc.

SpyGlass Pharma, Inc.

Summit Therapeutics Inc.

Generate Biomedicines, Inc.

Dilution score: 66/100 (HIGH), 2.2 months cash

13F fund flow: neutral, ? institutional managers

106007 PubMed publications found for CNS , .

Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review.

Multicentre, double-blind, randomised, placebo-controlled study on the prophylactic use of naldemedine for opioid-induced nausea and vomiting in patients with cancer (POSEIDON study): a protocol paper.

Remimazolam versus propofol for procedural sedation in hysteroscopic surgery: a meta-analysis of randomized controlled trials.

Comparison of ultrasound-guided erector spinae plane block to intrathecal morphine for postoperative analgesia in patients undergoing elective lumbar fusion operations under general anesthesia: a randomized controlled trial.

Precipitants and clinical features of serotonin syndrome: a systematic review with patient-level analysis of published case reports and series.

Short interest: 2.5% of float, squeeze risk: LOW

SW convergence: 50/100 (Neutral), 0 bullish / 1 bearish signals

<article class="bts-verified-summary" data-ticker="CNSP">
<p>CNS Pharmaceuticals, Inc. (CNSP) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 1 Phase 2<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>CNSP has 1 Form 4 insider filing recorded at the SEC in the past 30 days<sup><a href="#fn-3">[3]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-06-17) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22CNS+Pharmaceuticals%2C+Inc.%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-06-17) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22CNS+Pharmaceuticals%2C+Inc.%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">SEC EDGAR · 0001729427 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22CNSP%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001729427

CNS Pharmaceuticals, Inc. (CNSP) — BioTechSigns Verified Summary

CNS Pharmaceuticals, Inc. (CNSP) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 2[1].

CNSP has 1 Form 4 insider filing recorded at the SEC in the past 30 days[3].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22CNS+Pharmaceuticals%2C+Inc.%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22CNS+Pharmaceuticals%2C+Inc.%22&aggFilters=status%3Arec%2Cact
[3] SEC EDGAR, 0001729427. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22CNSP%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17

This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria.

A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.